At the news
? BULLISHIMPACT 7/10 6-K filed Jun 15, 2026 at 06:02 ET
Ascendis Pharma reported Week 182 data from the Phase 3 PaTHway Trial for TransCon PTH (palopegteriparatide) in hypoparathyroidism, showing sustained efficacy and safety over 3.5 years. Key results include 86% responders, 100% independence from active vitamin D, 96% independence from therapeutic calcium, normalized kidney function, and no anti-PTH antibodies. The data reinforce the drug's long-term value proposition.
- 86% of patients met the multi-component responder endpoint (normal serum calcium, no active vitamin D, ≤600 mg/day calcium).
- 100% of patients achieved independence from active vitamin D.
- 96% of patients achieved independence from therapeutic doses of calcium (<600 mg/day).
- Mean eGFR increased by 11.0 mL/min/1.73m² from baseline and was maintained through Week 182, contrasting with age-related decline.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access